2020 Partners




BrightInsight, a Flex Company, provides the leading global regulated digital health platform for biopharma and medtech. Our medical-grade Internet of Things (IoT) platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement.
The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with security, privacy and regulatory requirements.






IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.






Noom is the world’s leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their habits for the long-term. More than 50 million people have benefited from Noom’s behavior change courses.
The company is headquartered in New York City with offices in Seoul and Tokyo.






We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.
The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.
We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.






Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes.
Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.






JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.
We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.
Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.












Sanofi Digital Medicine, under the Chief Medical Office, improves patient outcomes through the development of innovative technology-driven solutions that when combined with drugs, improve treatment efficacy, safety, adherence and overall experience.
Be part of the 300+ person audience of senior executives who are driving forward the development of Digital Therapeutics
Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers
Established in 2017, the DTx series is the home for the Digital Therapeutics community
The DTx Series is my go-to place for staying up-to-date and meeting all of the key players in this promising new digital health category.
I am excited to attend DTx for the fourth time. Whether as a presenter or part of the audience, I learn so much from other Digital Therapeutic executives and attendees about topics ranging from clinical trials to commercialization and everything in between.
I have been to the two editions of DTx West and I’m looking forward to attending DTx East this year. The conference brings together key leaders from across the digital health space to discuss new ideas and ongoing trends that are useful takeaways to bring back to my team.
“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”
“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”
“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”
“DTx is a great event! there is a great mix of digital innovators and large companies which deliver high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions”
Speaker Faculty


Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.








Mark Bini is the Vice President of Innovation and Member Experience at Express Scripts. Since 2008, Mark has been a key contributor to the advancement of Express Scripts’ solution portfolio. Over this time, he has worked with other thought leaders to design and employ an industry-leading, behavior-centric approach to innovation that places clients and members in the “front seat” of product development. Mark is also responsible for Express Scripts’ suite of digital therapeutic solutions that includes remote monitoring solutions for diabetes, asthma, and medication non-adherence. Mark’s approach to innovation and the solutions that have spawned from it have played a key role in Express Scripts being named to Forbes’ World’s Most Innovative Companies.














Anil is a physician executive based in the Boston area and has over 20 years of global healthcare and biopharmaceutical experience. He studied medicine in Ireland and worked clinically in the Irish healthcare system before moving to the biopharmaceutical industry where he has held roles of increasing responsibility across different companies, different therapeutic areas and different geographies.
Anil’s interest in developing world healthcare started while he was studying medicine at the Royal College of Surgeons in Ireland, where he raised money to purchase medical supplies for a rural health clinic in Tanzania, East Africa, and delivered them personally as well as working in the clinic for 3 months. More recently he has been instrumental in establishing a charitable access program to rare disease medicines which is now operating across 10 countries.


Trina has built an extensive career in addressing prevention, wellbeing, behavior change, and emotional health by translating evidence into practice in healthcare in Ireland and the USA. Trina has been working in the digital space since 2010.
Trina is a Senior Principal Consultant in Prevention, Wellness, and Digital Health at Kaiser Permanente’s Care Management Institute. Trina obtained a Ph.D. in health psychology from University College Cork, Ireland. Trina has published on the topic of Obesity and has spoken at numerous conferences. Trina has consulted on games for health, including Kaiser Permanente’s “Amazing Food Detective” and on tech solutions for weight management (Picture it!) in collaboration with Ayogo. Trina is currently co-lead for Project Chamai (Greek for “grounded”) to deploy an ecosystem of digital mental health tools in Kaiser Permanente to support emotional wellness.
Trina has been invited to act as an expert advisor and to educate numerous organizations, including the Centers for Disease Control, CMS, National Committee for Quality Assurance (NCQA), National Quality Forum (NQF), Prescription for Physical Activity Task Force, and the Obesity Society and Ayogo. Trina is a member of the Society for Behavioral Medicine (SBM), the American Psychological Association (APA), The Obesity Society (TOS), and Digital Medicine Society (DiME).
Trina enjoys bringing the evidence to life for front line teams and implementing technology solutions to support people on their journey toward health.






In his role as Associate at OMERS Ventures, Mark is responsible for researching and executing on investment opportunities in growth-oriented, disruptive technology companies.
Prior to joining OMERS Ventures, Mark was the Head of Strategy and Head of Sales at SAP.iO, the venture and incubation group of SAP – the world’s largest enterprise software company. Mark was responsible for conducting diligence on new startups and working with founders to build and execute sales strategies.
Before SAP.iO, Mark held roles in Sales and Presales within SAP helping Fortune 500 companies drive digital transformation by adopting intelligent enterprise applications. Mark worked across the portfolio covering core ERP and related cloud applications.
Mark holds an HBA from the Ivey Business School from the University of Western Ontario


Kal Patel has over 20 years of experience in pharma, medtech and regulated digital health. Prior to joining BrightInsight, he was Chief Commercial Officer for Doctor on Demand, now the nation’s largest video-medicine provider, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.
Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of digital products in connected devices, advanced algorithms/decision making and next-generation marketing, where he launched multiple regulated devices. Kal also serves as a Senior Advisor in Digital Health to the Boston Consulting Group and various digital health startups


Saeju Jeong, CEO and co-founder of Noom, is a serial entrepreneur and tech company angel investor. Noom is the world’s largest behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of thousands of personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom’s behavior change courses, and Noom’s platform is already being used by leading healthcare and pharmaceutical companies like Novo Nordisk to improve treatment outcomes for patients worldwide.
Noom, Inc. is backed by Sequoia Capital, RRE, Samsung and Qualcomm.






Kara Tibbe leads health system wide care transformation initiatives centered around digital health innovation. At Spectrum Health, she leads projects focused on virtual and mobile health integration within primary and specialty care. Spectrum Health is the first health system in the US to integrate IQVIA’s App prescription platform “AppScript” into the EMR which enables mobile app prescriptions to be embedded into clinician workflow, a project that Kara leads. Kara’s role encompasses vetting digital therapeutics for employer and health care settings and operationalizing into seamless patient care.
Her background is in Business Administration and Science.


Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.


Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.


Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, the State and Treasury Departments, and the United Nations Development Program. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won SXSW’s best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.










Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.


Rebecca Lyons is a program manager on Blue Shield of California’s Enhanced Clinical Program & HealthCare value solutions team . Prior to a brief time away to work on patient engagement at a biotech startup, she coordinated the partnerships with medical groups and hospitals while a program manager on BSC’s Accountable Care Organization team. Prior to BSC, she held various positions in health care delivery such as performance improvement, program management and clinical research coordinating at various institutions such as Cedars-Sinai Health System, Rady Children’s Hospital, San Diego and Columbia-NY Presbyterian Hospital. She holds an undergraduate degree in Developmental Psychology from UC San Diego and an MPH from Columbia University.


Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.










Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow’s evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past “40 under 40“ who started her career as a nurse and has worked in healthcare, education and technologies companies.




Ken is a regulatory affairs and business development lead at CureApp North America. He is specialized in US regulatory compliance with a strong engineering background. Before joining CureApp, he worked for regulatory compliance and business consulting company where he completed more than 14 regulatory submissions ranging from De Novo and 510(k) to Q-subs (Pre-sub, submission issue, supplemental) and variance requests.
With a variety of regulatory submission experience for products from early to late stages of development, he is currently responsible for CureApp’s US regulatory compliance, acting as a vital liaison between Japanese and US regulatory agencies.
In Japan, CureApp recently completed a phase III clinical trial and regulatory submission to the Japanese PMDA for a smoking cessation app. CureApp would like to share insights from outside of the US regulatory environment at the DTx East meeting.






Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.


Sharief Taraman, M.D. is the Chief Medical Officer at Cognoa, Inc., a Silicon Valley based startup that develops artificial intelligence-based digital diagnostics and personalized therapeutics that provide accurate, earlier diagnoses and more effective treatments to improve outcomes and lower behavioral healthcare costs. He is a Magna Cum Laude graduate of the University of Michigan having majored in Biochemistry. He completed his medical education at Wayne State University School of Medicine in 2006 and went on to complete residency training in Pediatrics and Pediatric Neurology at the Children’s Hospital of Michigan. Dr. Taraman is dual board certified in Neurology with special qualifications in child neurology from the American Board of Psychiatry and Neurology and in Clinical Informatics from the American Board of Preventative Medicine. He remains clinically active as the Division Chief of the CHOC Children’s Specialists Pediatric Neurology Division and a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine. Dr. Taraman is active in the community as a board member of the AAP Orange County Chapter, Irvine Unified School District Medical Advisory Board, and volunteering for Girl Scouts of Orange County and the Capistrano Unified School District.




Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.


Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.


Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.


Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.
With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.
A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.




Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world.
For over 25 years Joel has helped payers, employers, providers and suppliers achieve better patient outcomes at a lower cost of care using new health technology. Helping to lead the charge for healthcare innovation, Joel will share how employers, insurers, and other healthcare payers are adopting Click’s clinically-validated digital therapeutics as key components to population health strategies.
While at Johnson & Johnson as Director of Payer Relations and with Walgreens as Vice President of Market Development Joel initiated pay for performance and shared savings models of value-based purchasing with payers and health systems. Joel also led commercial efforts with Sanofi Aventis to help providers contain the exploding costs associated with chronic conditions such as diabetes and cardiovascular disease.
Joel graduated from DePaul University in Chicago and later completed a Fellowship in healthcare leadership with the Washington DC based Advisory Board Company.


Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.
Thursday, 20th February Summit Workshops
- Workshop 1: The Business of Digital Therapeutics
- Workshop 2: Separating the Digital from the Traditional
Debra Reisenthel, Founding CEO, Palo Alto Health Sciences
Everett Crosland, SVP of Market Access, Reimbursement & Government Affairs, AppliedVR
Jonas Duss, US Chief Executive Officer, Kaia Health
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics
- A brief overview of the various business models adopted by digital therapeutic companies
- An insight into the various routes to market
- Can DTx companies exist with both FDA and Non-FDA regulated therapeutics or do you have to “pick a side”
Splitting into smaller groups, you will discuss the intricacies of the business of digital therapeutics and hear views on how best to successfully run a business in the DTx industry.
- What are the current business models being used within the industry and which are demonstrating the most success?
- How do some business models favor certain types of digital therapeutic over others?
- Can a digital therapeutic company successfully develop and market both FDA & non-FDA regulated digital therapeutics?
- What are the route to market opportunities available to the DTx industry?
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.
Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:
- A deeper understanding of the various business models demonstrated by digital therapeutic companies
- Up-to-date information on business models of varying successes in the current industry
- A clear understanding of if it’s possible to successfully a dual entity business or if companies truly have to “pick a side”
- A clear understanding of current routes to market and their intricacies
- Your questions answered by industry leaders and your peers
Acacia Parks, Chief Scientist, Happify
Jenna Carl, VP of Clinical Development & Medical Affairs, Big Health
Derek Richards, Chief Science Officer, SilverCloud Health
Anil Jina, Chief Medical Officer, Akili Interactive
- How do digital therapeutic clinical trials differ from traditional drug trials?
- An introduction of comparison groups and digital trial design
Led by leaders in the industry all with in-depth experience of DTx clinical trials, this panel will dive into clinical trial considerations when designing trials for digital therapeutics
- What are the requirements when designing digital therapeutic clinical trials?
- What does the FDA require from clinical trials for them to be acceptable?
- What does a SHAM/placebo look like in the DTx clinical trial?
- Should DTx companies and the FDA be working together to produce the right SHAM for each trial?
This is your chance to finalize your notes and prepare questions for the workshop leaders and your peers for after the break!
Splitting into smaller groups, each group will discuss their own views on digital therapeutic clinical trials and work on how best to move forward in this space.
- What are the current issues we face when designing clinical trials for digital therapeutics?
- What considerations should you have in mind when designing SHAM trials?
- What are the current guidelines for DTx clinical trials outlined by the FDA?
- How can we work with governing bodies to ensure DTx clinical trials are both suitable and feasible?
- What does a suitable and usable SHAM trial look like?
Representatives from each group will share their main points from their discussion with the whole workshop.
Workshop leaders and members from all groups will facilitate the discussion with their own thoughts and questions in this collaborative session.
Summary thoughts will be shared by workshop leaders and all participators will leave with the below:
- A clear understanding of the clinical trial landscape for digital therapeutics
- A deeper understanding of how best to build a SHAM/placebo for a DTx clinical trial
- An understanding of current FDA clinical trial guidelines in the space
- A greater understanding of important considerations to keep in mind when designing a DTx clinical trial
- Your questions answered by industry-leading experts and your peers
Summit Agenda
- Day 1: Tuesday, 18th February
- Day 2: Wednesday, 19th February
Adam Kaufman, President & CEO, Canary Health
Bryce Williams, VP, Lifestyle Medicine, Blue Shield of California
Alex Petrov, Founder & CEO, Yes Health
Kevin Appelbaum, Co-Founder & CEO, Better Therapeutics
Saeju Jeong, Co-Founder & CEO, Noom
Moderated by Brent Vaughan, Chief Executive Officer, Cognoa
Sean Duffy, Co-Founder & CEO, Omada Health
Rebecca Lyons, Program Manager, Principal, Enhanced Clinical Programs,Blue Shield of California
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Peter Hames, Co-Founder & CEO, Big Health
Attendees are welcome to jump between tracks as they choose
Defining Evidence Standards for Digital Therapeutics
Chair: Acacia Parks, Chief Scientist, Happify
Acacia Parks, Chief Scientist, Happify
Representative from IQVIA
Veena Rao, Senior Director, Search & Evaluation, Device Delivery, Connected Systems & Digital Health, Eli Lilly
Mark Bini, VP, New Solutions, Express Scripts
Jo Masterson, Co-Founder. CPO & COO, 2morrow Inc.
Building the Value Proposition for Digital Therapeutics
Chair: Adam Kaufman, President & CEO, Canary Health
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics
Jonathon Hodgson, Senior Principal, Promidian, an EVERSANA company
Jeff Abraham, VP of Market Access & Trade, Akili Interactive
Jennifer LaGuardia, Senior Director of Behaviour Science, Omada Health
Andy Molnar, Senior Director, Market Access, Cognoa
Clare Purvis, Director, Behaviour Sciences, Headspace
Derek Richards, Chief Science Officer, Silvercloud Health
Moderated by Sharief Taraman, Chief Medical Office, Cognoa
Debra Reisenthel, Founding CEO Palo Alto Health Sciences
Jenna Carl, VP of Clinical Development & Medical Affairs, Big Health
Jonas Duss, US Chief Executive Officer, Kaia Health
Megan Oser, VP of Clinical Innovation, Mahana Therapeutics
Chris Wasden, Head of HappifyDTx, Happify Health
Mikael Eliasson, Global Head of Innovation, Neuroscience Product Development, Genentech
Moderated by Ed Cox, CEO, Dthera Sciences
Pierre Leurent, Founder and CEO, Voluntis
Kal Patel, Co-Founder & CEO, Bright Insight, a Flex Company
Eddie Martucci, Founder & CEO, Akili Interactive
Megan Coder, Executive Director, Digital Therapeutics Alliance
Adam Kaufman, President & CEO, Canary Health
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics
Chris Hogg, Chief Commercial Officer, Propeller Health
Timothy Kern, Vice President, Strategy & Business Development, ResMed
Moderated by Joel Sangerman, Chief Commercial Officer, Click Therapeutics
Elli Kaplan, Co-Founder & CEO, Neurotrack
Chris Hogg, Chief Commercial Officer, Propeller Health
Anand Iyer, Chief Strategy Officer, Welldoc
Liz Rockett, Director, Kaiser Permanente Ventures
Vas Bailey, Partner, Artis Ventures
David Stevenson, Managing Director, Merck Global Health Innovation Fund
Mark Goad, Associate, OMERS Ventures
Siva Nadarajah, Co-Founder & President, JOGO Health
Kenichiro Nishii, Lead, Regulatory Affairs and Business Development, CureApp
David Cox, Co-Founder & Chief Digital Officer, Closed Loop Medicine
Trina Histon, Senior Principal Consultant, Prevention, Wellness and Digital Health, Kaiser Permanente
Ben Rosner, Assistant Producer, UCSF
Rajan Merchant, Allergy, Asthma, and Clinical Immunology Specialist,Woodland Clinic Medical Group
Kara Tibbe, Training & Development Specialist, Spectrum Health
Pablo Panteoloni, VP & General Manager of Health, Headspace
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics


DTx West Venue - The Marriott, San Mateo
We strive to provide inspirational venues that can provide the space needed for an open and widely networked event.
The 2020 summit is back at the Marriott San Mateo, a contemporary hotel just 10 minutes from SFO airport. For 2020 space is bigger and better.
Blending the look and feel of a first class resort with comfort and state of the art conference amenities this venue is the perfect place for learning, networking and relaxing.
Bedrooms can be booked directly with the hotel. We anticipate high demand and recommend that you book early to secure the best possible rate. The Marriott does not offer an exclusive rate for DTx attendees. We have included, in the welcome pack, details of alternative hotels close to the DTx venue.
Partner with us
PARTNERSHIPS
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx West 2020 is the seventh summit in the DTx series. We are expecting 300 people at the summit in San Mateo, which is what our attendees and partners tell us is the optimum size
We believe that getting the right mix of partners is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world-class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
Get in touch today to learn more and avoid missing out!


Register for the Event
Early Booking Price expires November 22nd.
For pricing and booking options please click the button to go to the registration page.